Tech Company Financing Transactions
Raze Therapeutics Funding Round
Raze Therapeutics closed a $24 million Series A funding round on 10/14/2014. Investors included Astellas Venture Capital, Atlas Venture and MPM Capital.
Transaction Overview
Company Name
Announced On
10/14/2014
Transaction Type
Venture Equity
Amount
$24,000,000
Round
Series A
Investors
Proceeds Purpose
Proceeds from the financing will be used to advance the development of a new class of therapeutics that fight cancer by targeting mitochondrial one-carbon (1C) metabolism -- fundamental metabolic pathways necessary for tumors to grow and survive.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
400 Technology Sq. 10th Floor
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Raze Therapeutics is a biotechnology company dedicated to the discovery and development of a new class of oncology therapeutics that target fundamental metabolic pathways driving cancer growth and survival.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jason Rhodes
Chief Scientific Officer
Mark Manfredi
VP - Bus. Development
Adam Friedman
Browse more venture capital transactions:
Prev: 10/14/2014: Zero Motorcycles venture capital transaction
Next: 10/14/2014: Goodzer venture capital transaction
Share this article
News on VC Transactions
We report on funding rounds that are announced publicly. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs